Abstract：
For acute ischemic stroke treatment, the limitations of treatment methods and the high incidence of perioperative complications seriously affect the survival rate and postoperative recovery of patients. Human umbilical cord mesenchymal stem cells (hucMSCs) have multi-directional differentiation potential and immune regulation function, which is a potential cell therapy. The present investigation involved developing a model of cerebral ischemia-reperfusion injury by thrombectomy after middle cerebral artery occlusion (MCAO) for 90 min in rats and utilizing comprehensive multi-system evaluation methods, including the detection of brain tissue ischemia, postoperative survival rate, neurological score, anesthesia recovery monitoring, pain evaluation, stress response, and postoperative pulmonary complications, to elucidate the curative effect of tail vein injection of hucMSCs on MCAO\'s perioperative complications. Based on our research, it has been determined that hucMSCs treatment can reduce the volume of brain tissue ischemia, promote the recovery of neurological function, and improve the postoperative survival rate of MCAO in rats. At the same time, hucMSCs treatment can prolong the time of anesthesia recovery, relieve the occurrence of delirium during anesthesia recovery, and also have a good control effect on postoperative weight loss, facial pain expression, and lung injury. It can also reduce postoperative stress response by regulating blood glucose and serum levels of stress-related proteins including TNF-α, IL-6, CRP, NE, cortisol, β-endorphin, and IL-10, and ultimately promote the recovery of MCAO\'s perioperative complications.
摘要：
对于急性缺血性中风治疗，治疗方法的局限性和围手术期并发症的高发生率严重影响患者的生存率和术后恢复。人脐带间充质干细胞(hucMSCs)具有多向分化潜能和免疫调节功能,这是一种潜在的细胞疗法。本研究涉及通过大鼠大脑中动脉阻塞（MCAO）后90分钟的血栓切除术建立大鼠脑缺血再灌注损伤模型，并利用综合多系统评估方法，包括检测脑组织缺血，术后生存率,神经评分,麻醉恢复监测,疼痛评估，应激反应，术后肺部并发症，目的探讨尾静脉注射hucMSCs治疗MCAO围手术期并发症的疗效。根据我们的研究,已经确定hucMSCs治疗可以减少脑组织缺血的体积，促进神经功能的恢复，提高MCAO大鼠术后存活率。同时,hucMSCs治疗可延长麻醉恢复时间,缓解麻醉恢复期间谵妄的发生，并且对术后体重减轻也有很好的控制作用，面部疼痛的表情，和肺损伤。它还可以通过调节血糖和包括TNF-α在内的应激相关蛋白的血清水平来减少术后应激反应。IL-6,CRP,NE,皮质醇,β-内啡肽,并最终促进MCAO围手术期并发症的恢复。
